{"id":"W3135425547","doi":"10.1200/jco.2021.39.6_suppl.325","title":"UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Discontinuation; Oncology; Chromophobe cell; Adverse effect; Cancer; Clear cell; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007264477,0.0005298695,0.001045774,0.0002502626,0.0003182194,0.0004919603,0.0005892434,0.0008815058,0.01523983],"category_scores_gemma":[0.0004001429,0.0003328606,0.0008890353,0.0002189647,0.000188333,0.0005336211,0.0003401966,0.00102559,0.002625465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009240496,"about_ca_system_score_gemma":0.001131186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001262059,"about_ca_topic_score_gemma":0.00515133,"domain_scores_codex":[0.9998234,0.00005577339,0.00001452033,0.00004322801,0.00001677274,0.00004631067],"domain_scores_gemma":[0.9998604,0.00001633189,0.00002805775,0.00001310986,0.0000122895,0.000069826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5647185,0.03207142,0.01444191,0.001966185,0.001510554,0.0002183899,0.0003508731,0.001875085,0.03866987,0.0006544788,0.01688322,0.3266395],"study_design_scores_gemma":[0.4225496,0.4306846,0.07269178,0.0004694707,0.002191709,0.0006431197,0.0001642579,0.002981222,0.0140102,0.0005221657,0.05302118,0.00007072496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771286,0.005021389,0.0004765172,0.0005291157,0.0002702068,0.004844888,0.002873191,0.0002192678,0.008636828],"genre_scores_gemma":[0.9793676,0.001933248,0.002021845,0.0008124512,0.00008786221,0.004285228,0.002857764,0.0000331205,0.008600879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01523983,"threshold_uncertainty_score":0.05098236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06523054393215995,"score_gpt":0.3812463822326602,"score_spread":0.3160158383005003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}